A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Uronis, Hope E, Cushman, Stephanie M, Bendell, Johanna C, Blobe, Gerard C, Morse, Michael A, Nixon, Andrew B, Dellinger, Andrew, Starr, Mark D, Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699843/
https://www.ncbi.nlm.nih.gov/pubmed/23930208
http://dx.doi.org/10.1002/cam4.65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699843/
https://www.ncbi.nlm.nih.gov/pubmed/23930208
http://dx.doi.org/10.1002/cam4.65

Ejemplares similares